{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:39:18Z","timestamp":1784774358905,"version":"3.55.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2023,5,16]]},"abstract":"<jats:sec sec-type=\"background\" xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">Prior national data showed a substantial in\u2010hospital mortality in septal myectomy (SM) with an inverse volume\u2013outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume\u2013outcome relationship in obstructive hypertrophic cardiomyopathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              All septal reduction therapy admissions between 2010 to 2019 in the United States were analyzed using the National Readmission Databases. Hospitals were stratified into tertiles of low\u2010, medium\u2010, and high\u2010volume based on annualized procedural volume of alcohol septal ablation and SM. Of 19\u2009007 patients with obstructive hypertrophic cardiomyopathy who underwent septal reduction therapy, 12\u2009065 (63%) had SM. Two\u2010thirds of hospitals performed \u22645 SM or alcohol septal ablation annually. In all SM encounters, 482 patients (4.0%) died in\u2010hospital post\u2010SM. In\u2010hospital mortality was &lt;1% in 1505 (88.4%) hospitals, 1% to 10% in 30 (1.8%) hospitals, and \u226510% in 167 (9.8%) hospitals. There were 63 (3.7%) hospitals (averaging 2.2 SM cases\/year) with 100% in\u2010hospital mortality. Post\u2010SM (in low\u2010, medium\u2010, and high\u2010volume centers, respectively), in\u2010hospital mortality (5.7% versus 3.9% versus 2.4%,\n              <jats:italic>P<\/jats:italic>\n              =0.003; adjusted odds ratio [aOR], 2.86 [95% CI, 1.70\u20134.80],\n              <jats:italic>P<\/jats:italic>\n              =0.001), adverse in\u2010hospital events (21.30% versus 18.0% versus 12.6%,\n              <jats:italic>P<\/jats:italic>\n              =0.001; aOR, 1.88 [95% CI, 1.45\u20132.43],\n              <jats:italic>P<\/jats:italic>\n              =0.001), and 30\u2010day readmission (17.1% versus 12.9% versus 9.7%,\n              <jats:italic>P<\/jats:italic>\n              =0.001; adjusted hazard ratio, 1.53 [95% CI, 1.27\u20131.96],\n              <jats:italic>P<\/jats:italic>\n              =0.001) were significantly higher in low\u2010 versus high\u2010volume hospitals. For alcohol septal ablation, the incidence of in\u2010hospital death and all other outcomes did not differ by hospital volume.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">In\u2010hospital SM mortality was 4% with an inverse volume\u2010mortality relationship. Mortality post\u2010alcohol septal ablation was similar across all volume tertiles. Morbidity associated with SM was substantial across all volume tertiles.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.122.028693","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T10:10:35Z","timestamp":1684145435000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1161","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-5415","authenticated-orcid":false,"given":"Ahmed M.","family":"Altibi","sequence":"first","affiliation":[{"name":"Hypertrophic Cardiomyopathy Center, Division of Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9592-6452","authenticated-orcid":false,"given":"Fares","family":"Ghanem","sequence":"additional","affiliation":[{"name":"Internal Medicine Department East Tennessee State University Johnson City TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hypertrophic Cardiomyopathy Center, Division of Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3162-6500","authenticated-orcid":false,"given":"Miriam","family":"Elman","sequence":"additional","affiliation":[{"name":"Hypertrophic Cardiomyopathy Center, Division of Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University Portland OR USA"},{"name":"OHSU\u2010PSU School of Public Health Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1567-6006","authenticated-orcid":false,"given":"Joaquin","family":"Cigarroa","sequence":"additional","affiliation":[{"name":"Hypertrophic Cardiomyopathy Center, Division of Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4078-9064","authenticated-orcid":false,"given":"Babak","family":"Nazer","sequence":"additional","affiliation":[{"name":"Hypertrophic Cardiomyopathy Center, Division of Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University Portland OR USA"},{"name":"Now with Division of Cardiovascular Medicine University of Washington Medical Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4254-006X","authenticated-orcid":false,"given":"Howard K.","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic Surgery Knight Cardiovascular Institute, Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Hypertrophic Cardiomyopathy Center, Division of Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.644682"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.06.011"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021332"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000937"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318223e2bd"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.06.1333"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2018.08.068"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2022.05.062"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.0252"},{"key":"e_1_3_1_11_2","unstructured":"CY 6031 study will evaluate the effects of treatment with aficamten (CK\u20103773274) . Over a 24\u2010week period on cardiopulmonary exercise capacity and health status in patients with symptomatic oHCM. ClinicalTrials.gov. Accessed June 9 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05186818."},{"key":"e_1_3_1_12_2","unstructured":"Overview of the Nationwide Readmissions Database (NRD) . Agency for Healthcare Research and Quality. Accessed May 1 2022. https:\/\/www.hcup\u2010us.ahrq.gov\/nrdoverview.jsp"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3462-1"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-2070"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.122.028693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T12:35:05Z","timestamp":1715603705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.122.028693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,5,16]]}},"alternative-id":["10.1161\/JAHA.122.028693"],"URL":"https:\/\/doi.org\/10.1161\/jaha.122.028693","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"2022-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e028693"}}